Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,692 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-in-man study evaluating the safety and efficacy of a second generation biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo coronary lesions: clinical, Angiographic, and OCT outcomes of CREDIT-1.
Wang G, Sun Z, Jin Q, Xu K, Li Y, Wang X, Ma Y, Liu H, Zhao X, Wang B, Deng J, Guan S, Ge M, Wang X, Xu B, Han Y. Wang G, et al. Among authors: xu k, xu b. Catheter Cardiovasc Interv. 2015 Mar;85 Suppl 1:744-51. doi: 10.1002/ccd.25862. Epub 2015 Feb 19. Catheter Cardiovasc Interv. 2015. PMID: 25630447 Clinical Trial.
Impact of six versus 12 months of dual antiplatelet therapy in patients with drug-eluting stent implantation after risk stratification with the residual SYNTAX score: Results from a secondary analysis of the I-LOVE-IT 2 trial.
Qiu M, Li Y, Li J, Xu K, Jing Q, Dong S, Jin Z, Zhao P, Xu B, Han Y. Qiu M, et al. Among authors: xu k, xu b. Catheter Cardiovasc Interv. 2017 Mar;89(S1):565-573. doi: 10.1002/ccd.26948. Epub 2017 Feb 17. Catheter Cardiovasc Interv. 2017. PMID: 28211603 Clinical Trial.
Safety and efficacy of 6-month versus 12-month dual antiplatelet therapy in patients after implantation of multiple biodegradable polymer-coated sirolimus-eluting coronary stents: Insight from the I-LOVE-IT 2 trial.
Qi J, Li Y, Li J, Jing Q, Xu K, Gao C, Ma L, Zhang Z, Xu B, Han Y. Qi J, et al. Among authors: xu k, xu b. Catheter Cardiovasc Interv. 2017 Mar;89(S1):555-564. doi: 10.1002/ccd.26947. Catheter Cardiovasc Interv. 2017. PMID: 28318138 Clinical Trial.
Randomized comparison of novel biodegradable polymer and durable polymer-coated cobalt-chromium sirolimus-eluting stents: Three-Year Outcomes of the I-LOVE-IT 2 Trial.
Song L, Li J, Guan C, Jing Q, Lu S, Yang L, Xu K, Yang Y, Xu B, Han Y; I-LOVE-IT 2 Investigators. Song L, et al. Among authors: xu k, xu b. Catheter Cardiovasc Interv. 2018 Feb 15;91(S1):608-616. doi: 10.1002/ccd.27465. Epub 2018 Jan 11. Catheter Cardiovasc Interv. 2018. PMID: 29322619 Clinical Trial.
Safety and efficacy of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: One-year results from a prospective patient-level pooled analysis of NeoVas trials.
Xu K, Fu G, Xu B, Zhou Y, Su X, Liu H, Zhang Z, Yu B, Wang X, Han Y; NeoVas OPC Investigators. Xu K, et al. Among authors: xu b. Catheter Cardiovasc Interv. 2019 Feb 15;93(S1):832-838. doi: 10.1002/ccd.28067. Catheter Cardiovasc Interv. 2019. PMID: 30888736
12,692 results
You have reached the last available page of results. Please see the User Guide for more information.